Indication
Relapsed/Refractory
2 clinical trials
7 products
Clinical trial
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-01-28
Product
PomalidomideProduct
MezagitamabProduct
DexamethasoneClinical trial
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabStatus: Not yet recruiting, Estimated PCD: 2028-12-31
Product
BlinatumomabProduct
Inotuzumab OzogamicinProduct
Hyper-CVADProduct
Mini-hyper-CVD